started · updated
Isomorphic Labs secures $5 billion in Series C funding
Isomorphic Labs, an AI-driven drug design company, has closed a $5 billion Series C funding round. The investment round was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz, Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund.
Founded by DeepMind co-founder Sir Demis Hassabis, the company aims to use artificial intelligence to model biology at a molecular level. The funding will be used to scale its proprietary drug design engine, IsoDDE, and accelerate its therapeutic candidate pipeline. The company expects to begin its first clinical trials before the end of the year.
Alphabet continues to be a significant investor in the firm. Isomorphic Labs seeks to transition drug design from traditional laboratory speeds to a software-driven loop, aiming to reduce the time and cost associated with developing new medicines.
Entities
Alphabet · Demis Hassabis · Greenoaks · Isomorphic Labs · Sequoia Capital